Emerald Advisers LLC Has $23.26 Million Position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Emerald Advisers LLC lessened its stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 1.9% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 811,680 shares of the specialty pharmaceutical company’s stock after selling 15,622 shares during the period. Emerald Advisers LLC owned 2.52% of Collegium Pharmaceutical worth $23,255,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. TD Private Client Wealth LLC lifted its position in shares of Collegium Pharmaceutical by 39.5% during the 3rd quarter. TD Private Client Wealth LLC now owns 1,707 shares of the specialty pharmaceutical company’s stock valued at $66,000 after acquiring an additional 483 shares during the period. KBC Group NV lifted its position in shares of Collegium Pharmaceutical by 72.5% during the 4th quarter. KBC Group NV now owns 2,336 shares of the specialty pharmaceutical company’s stock valued at $67,000 after acquiring an additional 982 shares during the period. Nisa Investment Advisors LLC lifted its position in shares of Collegium Pharmaceutical by 14.5% during the 4th quarter. Nisa Investment Advisors LLC now owns 2,493 shares of the specialty pharmaceutical company’s stock valued at $71,000 after acquiring an additional 316 shares during the period. Virtus Fund Advisers LLC acquired a new position in shares of Collegium Pharmaceutical during the 3rd quarter valued at $72,000. Finally, China Universal Asset Management Co. Ltd. lifted its position in shares of Collegium Pharmaceutical by 10.4% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,838 shares of the specialty pharmaceutical company’s stock valued at $196,000 after acquiring an additional 642 shares during the period.

Analysts Set New Price Targets

Several research firms have weighed in on COLL. HC Wainwright restated a “buy” rating and set a $50.00 price objective on shares of Collegium Pharmaceutical in a report on Friday, January 10th. Piper Sandler lowered their price objective on shares of Collegium Pharmaceutical from $37.00 to $36.00 and set a “neutral” rating on the stock in a report on Tuesday, February 4th. Finally, Needham & Company LLC upgraded shares of Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 price objective on the stock in a report on Friday, January 10th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, Collegium Pharmaceutical has a consensus rating of “Moderate Buy” and an average target price of $43.60.

Collegium Pharmaceutical Stock Performance

Shares of COLL stock opened at $30.05 on Friday. The firm has a 50-day moving average of $30.69 and a 200-day moving average of $32.67. The company has a market cap of $946.15 million, a P/E ratio of 12.95 and a beta of 0.99. The company has a debt-to-equity ratio of 3.43, a current ratio of 0.97 and a quick ratio of 0.88. Collegium Pharmaceutical, Inc. has a one year low of $27.28 and a one year high of $42.29.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its earnings results on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 EPS for the quarter, beating the consensus estimate of $1.54 by $0.09. The company had revenue of $181.95 million during the quarter, compared to the consensus estimate of $179.68 million. Collegium Pharmaceutical had a net margin of 14.78% and a return on equity of 104.67%. Equities research analysts forecast that Collegium Pharmaceutical, Inc. will post 5.62 EPS for the current fiscal year.

Insider Activity

In related news, EVP Shirley R. Kuhlmann sold 27,500 shares of the stock in a transaction dated Friday, January 10th. The shares were sold at an average price of $33.04, for a total transaction of $908,600.00. Following the completion of the transaction, the executive vice president now owns 119,184 shares in the company, valued at approximately $3,937,839.36. This represents a 18.75 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Colleen Tupper sold 1,949 shares of the stock in a transaction dated Thursday, March 6th. The shares were sold at an average price of $30.00, for a total transaction of $58,470.00. Following the transaction, the chief financial officer now owns 177,195 shares of the company’s stock, valued at approximately $5,315,850. The trade was a 1.09 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 109,193 shares of company stock worth $3,243,594 over the last quarter. Insiders own 3.98% of the company’s stock.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.